Phase 1 results disclosed Monday indicate the company’s protein-degrading drug can affect a tough-to-reach target called ...

University of Michigan spinoff company Courage Therapeutics is based in Massachusetts and develops medicines targeting ...

acquiring Carmot Therapeutics and partnering with Zealand, and AstraZeneca, partnering with Eccogene, have done. We should also note that while Novo's deal with Septerna involves a $195m upfront ...

Analysts' ratings for Septerna SEPN over the last quarter vary from bullish to bearish, as provided by 4 analysts. The table below provides a snapshot of their recent ratings, showcasing how ...

Novo Nordisk and Septerna have announced a new partnership worth $2.2bn to develop oral small molecule drugs for type 2 diabetes, obesity and other cardiometabolic diseases. The exclusive global ...

Shares of Septerna SEPN surged 51% on May 14 after ... Several other companies like Amgen AMGN and Viking Therapeutics are also making rapid progress in the development of GLP-1-based candidates ...

Novo Nordisk and Septerna have entered a global collaboration to develop oral small molecule therapies for obesity, type 2 diabetes, and other cardiometabolic diseases, initially targeting four ...

Shares of Septerna Inc. were soaring in Wednesday trading after the biotech clinched a partnership with Wegovy and Ozempic parent Novo Nordisk to collaborate on oral obesity and Type 2 diabetes ...

Investing.com -- Shares of Septerna, Inc. (Nasdaq:SEPN) surged 60% following the announcement of an exclusive global collaboration and license agreement with Novo Nordisk (NYSE:NVO) to develop oral ...

The deal is valued at up to $2.2bn, including more than $200m in upfront and near-term payments to Septerna. The partnership centres on the discovery and development of oral therapeutics aimed at ...

In a deal that could top out at about $2.2 billion, Septerna Inc. is getting $200 million up front from Novo Nordisk A/S in a collaboration to develop oral treatments for obesity, type 2 diabetes and ...